BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22086681)

  • 1. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
    Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
    Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
    Ma C; Huang T; Ding YC; Yu W; Wang Q; Meng B; Luo SX
    Int J Clin Exp Pathol; 2015; 8(6):6533-9. PubMed ID: 26261532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells.
    Bao B; Wang Z; Ali S; Kong D; Li Y; Ahmad A; Banerjee S; Azmi AS; Miele L; Sarkar FH
    Cancer Lett; 2011 Aug; 307(1):26-36. PubMed ID: 21463919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
    Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH
    Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
    Bao B; Ali S; Kong D; Sarkar SH; Wang Z; Banerjee S; Aboukameel A; Padhye S; Philip PA; Sarkar FH
    PLoS One; 2011 Mar; 6(3):e17850. PubMed ID: 21408027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells.
    Bao B; Wang Z; Ali S; Kong D; Banerjee S; Ahmad A; Li Y; Azmi AS; Miele L; Sarkar FH
    J Cell Biochem; 2011 Sep; 112(9):2296-306. PubMed ID: 21503965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
    Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
    Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a pancreatic cancer stem cell model using the SW1990 human pancreatic cancer cell line in nude mice.
    Pan Y; Gao S; Hua YQ; Liu LM
    Asian Pac J Cancer Prev; 2015; 16(2):437-42. PubMed ID: 25684468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
    PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
    Singh S; Chitkara D; Kumar V; Behrman SW; Mahato RI
    Cancer Lett; 2013 Jul; 334(2):211-20. PubMed ID: 23073476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.
    Sun Y; Ren D; Zhou Y; Shen J; Wu H; Jin X
    Cell Death Dis; 2021 Sep; 12(10):878. PubMed ID: 34564701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
    Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Li Y; VandenBoom TG; Kong D; Wang Z; Ali S; Philip PA; Sarkar FH
    Cancer Res; 2009 Aug; 69(16):6704-12. PubMed ID: 19654291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
    Vaz AP; Ponnusamy MP; Rachagani S; Dey P; Ganti AK; Batra SK
    Br J Cancer; 2014 Jul; 111(3):486-96. PubMed ID: 25003666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
    Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.